Market Analysis And Research Reports: Pharmaceuticals-and-healthcare

Showing posts with label Pharmaceuticals-and-healthcare. Show all posts

Wednesday, 3 October 2018

Global Topical Steroids Market Size, Growth Rate, Revenue, Price and Demand Worldwide 2025

In 2017, the global Topical Steroids market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the Topical Steroids market based on company, product type, application and key regions.

This report studies the global market size of Topical Steroids in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Topical Steroids in these regions.

This research report categorizes the global Topical Steroids market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter's Five Forces Analysis.

Request A Sample Copy of this Market Report @:
https://www.radiantinsights.com/research/global-topical-steroids-market-insights-forecast-to-2025/request-sample

The various contributors involved in the value chain of Topical Steroids include manufacturers, suppliers, distributors, intermediaries, and customers.

The key manufacturers in the Topical Steroids include:
• Merck
• Pfizer
• Novartis
• Abbott
• Roche
• Sanofi
• Eli Lilly
• Bayer
• Glaxosmithkline
• Galderma
• Aqua Pharmaceuticals
• Taro Pharmaceuticals
• Apotex Corporation
• Pure Tek Corporation
• Nu Care Pharmaceuticals,inc.
• Taro Pharmaceuticals U.S.A., Inc.
• Arbor Pharmaceuticals

Market Size Split by Type:
• Class I
• Class II
• Class III
• Class IV
• Class V
• Class VI
• Class VII

Market Size Split by Application:
• Treatment of Rash
• Treatment of Eczema
• Treatment of Dermatitis

Market size split by Region:
• North America
• United States
• Canada
• Mexico

The study objectives of this report are:
• To study and analyze the global Topical Steroids market size (value & volume) by company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025.
• To understand the structure of Topical Steroids market by identifying its various subsegments.
• To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
• Focuses on the key global Topical Steroids manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
• To analyze the Topical Steroids with respect to individual growth trends, future prospects, and their contribution to the total market.
• To project the value and volume of Topical Steroids submarkets, with respect to key regions (along with their respective key countries).
• To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
• To strategically profile the key players and comprehensively analyze their growth strategies.

Browse Full Research Report of this Market With TOC @:
https://www.radiantinsights.com/research/global-topical-steroids-market-insights-forecast-to-2025

In this study, the years considered to estimate the market size of Topical Steroids are as follows:
• History Year: 2013-2017
• Base Year: 2017
• Estimated Year: 2018
• Forecast Year 2018 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Topical Steroids market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contact Details:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
28 2nd Street, Suite 3036, San Francisco, CA 94105, United States
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com

Wednesday, 1 August 2018

Metabolic Disorders Drugs Market Top Manufacturers, Key Vendors and Regions By 2018

This report studies Metabolic Disorders Drugs in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2013 to 2018, and forecast to 2025.

By Regions, this report covers (we can add the regions/countries as you want):
• North America
• China
• Europe
• Southeast Asia
• Japan
• India

Request A Sample Copy Market Report @:
https://www.radiantinsights.com/research/global-metabolic-disorders-drugs-market-professional-survey-report-2018/request-sample

This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering:
• Zealand Pharma
• Rhythm
• OxThera
• Biophytis
• Biophytis
• Zafgen
• PerkinElmer
• Eternygen
• Pronutria Biosciences
• MedGenome
• CellCentric
• Nimbus Therapeutics
• Mitobridge
• Exelixis, Inc.
• Outpost Medicine
• Anchor Therapeutics
• Verva Pharmaceuticals

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into:
• Tablet
• Injection

By Application, the market can be split into:
• Diabetes
• Disorders of the Thyroid and Pituitary Gland
• Other

Browse Full Research Report of Market With TOC @:
https://www.radiantinsights.com/research/global-metabolic-disorders-drugs-market-professional-survey-report-2018

Table of Contents:

Global Metabolic Disorders Drugs Market Professional Survey Report 2018

1 Industry Overview of Metabolic Disorders Drugs
1.1 Definition and Specifications of Metabolic Disorders Drugs
1.1.1 Definition of Metabolic Disorders Drugs
1.1.2 Specifications of Metabolic Disorders Drugs
1.2 Classification of Metabolic Disorders Drugs
1.2.1 Tablet
1.2.2 Injection
1.3 Applications of Metabolic Disorders Drugs
1.3.1 Diabetes
1.3.2 Disorders of the Thyroid and Pituitary Gland
1.3.3 Other
1.4 Market Segment by Regions
1.4.1 North America
1.4.2 China
1.4.3 Europe
1.4.4 Southeast Asia
1.4.5 Japan
1.4.6 India

2 Manufacturing Cost Structure Analysis of Metabolic Disorders Drugs
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Metabolic Disorders Drugs
2.3 Manufacturing Process Analysis of Metabolic Disorders Drugs
2.4 Industry Chain Structure of Metabolic Disorders Drugs

Friday, 22 June 2018

United States Pharmaceutical Plant Extracts Market Research, Development, Analysis and Revenue, 2018

In this report, the United States Pharmaceutical Plant Extracts market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.

Geographically, this report splits the United States market into seven regions:
• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest

with sales (volume), revenue (value), market share and growth rate of Pharmaceutical Plant Extracts in these regions, from 2013 to 2025 (forecast).

Request A Sample Copy Of This Market Report @: https://www.radiantinsights.com/research/united-states-pharmaceutical-plant-extracts-industry-2018/request-sample

United States Pharmaceutical Plant Extracts market competition by top manufacturers/players, with Pharmaceutical Plant Extracts sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including:
• Indena
• Network
• Schwabe
• Pharmachem
• Naturex
• Ipsen
• Provital Group
• Bioforce
• Euromed
• Sabinsa
• Tsumura&Co
• Chenguang Biotech
• Rainbow
• BGG
• Organic Herb
• Conba Group
• Gaoke Group
• JiaHerb
• Green-Health
• Lgberry
• Layn
• Novanat
• LIWAH
• Xi'an High Tech
• Wagott Bio-Tech
• Active Ingredients
• Natural Remedies
• Bioprex Labs
• Arjuna Natural
• Alchem

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into:
By Types:
• Non-standardized Extracts
• Standardized Extracts

by Application Types:
• Herbal Extracts
• Phytochemicals
• Spices
• Essential Oils and Natural Extracts
• Flavors and Fragrances
• Others

Browse Full Research of This Market Report With TOC @: https://www.radiantinsights.com/research/united-states-pharmaceutical-plant-extracts-industry-2018

by Forms:
• Powder
• Liquid
• Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including:
• Medicine
• Food
• Cosmetic
• Others

Contact Details:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
28 2nd Street, Suite 3036, San Francisco, CA 94105, United States
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com

Global Artificial Joints Market is expected to each US$ 25.31 Bn By 2024

This report studies the global Artificial Joints market status and forecast, categorizes the global Artificial Joints market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, India, Southeast Asia and other regions (Central & South America, and Middle East & Africa).

The global Artificial Joints market is valued at xx million US$ in 2017 and is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx.x % between 2018 and 2025.

Request A Sample Copy Of This Market Report @: https://www.radiantinsights.com/research/global-artificial-joints-market-professional-survey-report-2018/request-sample

The major manufacturers covered in this report:
• Zimmer Holdings
• Johnson & Johnson
• Stryker
• Biomet
• Smith & Nephew
• Arthrex
• Link
• AESCULAP
• Wright Medical Technology
• Exactech
• SAMO
• Limacorporate

Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering:
• North America
• Europe
• China
• Japan
• India
• Southeast Asia
• Other regions (Central & South America, Middle East & Africa)

The regional scope of the study is as follows:
• North America
• United States
• Canada
• Mexico
• Asia-Pacific
• China
• India

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into:
• Ceramics Artificial Joints
• Alloy Artificial Joints
• Oxinium Artificial Joints
• Other

By Application, the market can be split into:
• Artificial Joints of Knee
• Artificial Joints of Hip
• Artificial Joints of Shoulder
• Other

The study objectives of this report are:
• To analyze and study the global Artificial Joints capacity, production, value, consumption, status (2013-2017) and forecast (2018-2025);
• Focuses on the key Artificial Joints manufacturers, to study the capacity, production, value, market share and development plans in future.
• Focuses on the global key manufacturers, to define, describe and analyze the market competition landscape, SWOT analysis.
• To define, describe and forecast the market by type, application and region.
• To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
• To identify significant trends and factors driving or inhibiting the market growth.
• To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
• To strategically analyze each submarket with respect to individual growth trend and their contribution to the market.
• To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
• To strategically profile the key players and comprehensively analyze their growth strategies.

Browse Full Research of This Market Report With TOC @: https://www.radiantinsights.com/research/global-artificial-joints-market-professional-survey-report-2018

In this study, the years considered to estimate the market size of Artificial Joints are as follows:
• History Year: 2013-2017
• Base Year: 2017
• Estimated Year: 2018
• Forecast Year 2018 to 2025

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders:
• Artificial Joints Manufacturers
• Artificial Joints Distributors/Traders/Wholesalers
• Artificial Joints Subcomponent Manufacturers
• Industry Association
• Downstream Vendors

Available Customizations:
• Regional and country-level analysis of the Artificial Joints market, by end-use.
• Detailed analysis and profiles of additional market players.

Contact Details:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
28 2nd Street, Suite 3036, San Francisco, CA 94105, United States
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com

Thursday, 6 July 2017

Market Development Report - Tryptophan 2,3 Dioxygenase - Pipeline Review, H1 2017: Radiant Insights, Inc

Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) pipeline Target constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies. The latest report Tryptophan 2,3 Dioxygenase Pipeline Review, H1 2017, outlays comprehensive information on the Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) Tryptophan 2, 3-dioxygenase is an enzyme that plays a critical role in tryptophan metabolism by catalyzing the first and rate-limiting step of the kynurenine pathway. It has specificity towards tryptamine and derivatives including Dand L-tryptophan, 5-hydroxytryptophan and serotonin. The molecules developed by companies in Preclinical and Discovery stages are 8 and 3 respectively. Report covers products from therapy areas Oncology and Central Nervous System which include indications Glioblastoma Multiforme (GBM), Melanoma, Bladder Cancer, Liver Cancer and Parkinson's Disease.

Browse Full Research Report With TOC: http://www.radiantinsights.com/research/tryptophan-2-3-dioxygenase-tryptamin-2-3-dioxygenase

Furthermore, this report also reviews key players involved in Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

The report provides a snapshot of the global therapeutic landscape for Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11)
The report reviews Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics and enlists all their major and minor projects
The report assesses Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics

Reasons To Buy:

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11)
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) development landscape
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

See More Reports of This Category by Radiant Insights:
http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare

About Radiant Insights,Inc
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

Contact Details:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
28 2nd Street, Suite 3036, San Francisco, CA 94105, United States
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Web: http://www.radiantinsights.com/

Serine/Threonine Protein Kinase ATR (FRAP Related Protein 1 Or ATR Or EC 2.7.11.1) - Pipeline Review, H1 2017: Market Report BY Radiant Insights, Inc

According to the recently published report 'SerineThreonine Protein Kinase ATR Pipeline Review, H1 2017'; Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.

Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) Serine/threonine-protein kinase ATR is an enzyme encoded by the ATR gene. It is required for cell cycle arrest and DNA damage repair in response to DNA damage. It has shown to phosphorylate checkpoint kinase CHK1, checkpoint proteins RAD17, and RAD9, as well as tumor suppressor protein BRCA1.

Browse Full Research Report With TOC:
http://www.radiantinsights.com/research/serine-threonine-protein-kinase-atr-ataxia-telangiectasia

The report 'SerineThreonine Protein Kinase ATR Pipeline Review, H1 2017' outlays comprehensive information on the Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 5 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Colorectal Cancer, Ovarian Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Non-Small Cell Lung Cancer, Solid Tumor, Breast Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer Squamous Cell Carcinoma, Lung Adenocarcinoma, Mantle Cell Lymphoma, Metastatic Breast Cancer, Pancreatic Cancer, Prostate Cancer and Small-Cell Lung Cancer.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1)
The report reviews Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
The report assesses Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) targeted therapeutics

Reasons To Buy:

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1)
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) development landscape
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

See More Reports of This Category by Radiant Insights:
http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare

About Radiant Insights,Inc
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

Contact Details:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
28 2nd Street, Suite 3036, San Francisco, CA 94105, United States
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Web: http://www.radiantinsights.com/

Research Report - Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase Or Idursulfase Or IDS Or EC 3.1.6.13) - Pipeline Review, H1 2017 BY Radiant Insights, Inc

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report Iduronate 2 Sulfatase Pipeline Review, H1 2017, outlays comprehensive information on the Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) Iduronate 2-sulfatase (IDS) is a sulfatase enzyme associated with Hunter syndrome. Iduronate 2-sulfatase is required for the lysosomal degradation of heparan sulfate and dermatan sulfate. Mutations in this X-chromosome gene that result in enzymatic deficiency lead to Hunter syndrome. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 4, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Genetic Disorders and Central Nervous System which include indications Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) and Cognitive Impairment.

Browse Full Research Report With TOC:
http://www.radiantinsights.com/research/iduronate-2-sulfatase-alpha-l-iduronate-sulfate-sulfatase

Furthermore, this report also reviews key players involved in Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

The report provides a snapshot of the global therapeutic landscape for Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)
The report reviews Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics and enlists all their major and minor projects
The report assesses Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics

Reasons To Buy:

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) development landscape
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Market Size Report - Granzyme B (C11 Or CTLA 1 Or Cathepsin G Like 1 Or Cytotoxic T Lymphocyte Proteinase 2 ) - Pipeline Review, H1 2017: Radiant Insights, Inc

Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) pipeline Target constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies. The latest report Granzyme B - Pipeline Review, H1 2017, outlays comprehensive information on the Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Browse Full Research Report With TOC:
http://www.radiantinsights.com/research/granzyme-b-c11-or-ctla-1-or-cathepsin-g-like-1

Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) - Granzyme B is a serine protease secreted by granules of cytotoxic lymphocytes (CTLs), natural killer cells (NK cells) and cytotoxic T cells. Granzyme B is crucial for the rapid induction of target cell death by apoptosis, induced by interaction with cytotoxic T cells. It activates the intracellular cascade of caspases finally resulting in the killing of the target cells. The molecules developed by companies in Preclinical and Discovery stages are 8 and 2 respectively. Report covers products from therapy areas Dermatology, Immunology, Cardiovascular, Metabolic Disorders, Central Nervous System, Oncology and Toxicology which include indications Diabetic Foot Ulcers, Aortic Aneurysm, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Hypertrophic Scars, Keloids, Skin Ulcers, Wounds, Abdominal Aortic Aneurysms, Alopecia, Dermal Ulcers, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Radiodermatitis, Rheumatoid Arthritis and Systemic Sclerosis (Scleroderma).

Furthermore, this report also reviews key players involved in Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

The report provides a snapshot of the global therapeutic landscape for Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79)
The report reviews Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) targeted therapeutics and enlists all their major and minor projects
The report assesses Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) targeted therapeutics

See More Reports of This Category by Radiant Insights:
http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare

Reasons To Buy:

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79)
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) development landscape
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

About Radiant Insights,Inc
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

Contact Details:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
28 2nd Street, Suite 3036, San Francisco, CA 94105, United States
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Web: http://www.radiantinsights.com/

Analysis Report- Caspase 6 (Apoptotic Protease Mch 2 Or CASP6 Or EC 3.4.22.59) - Pipeline Review, H1 2017 By Radiant Insights, Inc

According to the recently published report 'Caspase 6 - Pipeline Review, H1 2017'; Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) pipeline Target constitutes close to 5 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes.

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Caspase-6 is an enzyme encoded by the CASP6 gene. It is involved in the activation cascade of caspases responsible for apoptosis execution. It cleaves poly (ADP-ribose) polymerase.

Browse Full Research Report With TOC:
http://www.radiantinsights.com/research/caspase-6-apoptotic-protease-mch-2

The report 'Caspase 6 - Pipeline Review, H1 2017' outlays comprehensive information on the Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 1 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Gastrointestinal, Cardiovascular, Genito Urinary System And Sex Hormones, Immunology, Infectious Disease, Oncology and Respiratory which include indications Huntington Disease, Alzheimer's Disease, Autoimmune Hepatitis, Colorectal Cancer, Hepatitis C, Hepatocellular Carcinoma, Liver Cirrhosis, Liver Failure (Hepatic Insufficiency), Liver Transplant Rejection, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Pancreatic Islet Transplant Rejection, Portal Hypertension, Primary Sclerosing Cholangitis, Pulmonary Fibrosis and Renal Failure.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

The report provides a snapshot of the global therapeutic landscape for Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59)
The report reviews Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics and enlists all their major and minor projects
The report assesses Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics

Reasons To Buy:

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59)
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) development landscape
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Monday, 12 June 2017

Rivastigmine China Market Size Report 2017- Radiant Insights, Inc

This report studies Rivastigmine in China market, focuses on the top players in China market, with capacity, production, price, revenue and market share for each manufacturer, covering:

LGM Pharma
BOC Sciences
Alfa Chemistry
Waterstone Technology
2A PharmaChem
3B Scientific
Hubei lansan Biochemical Pharmaceutical
Suzhou Xinkai Bio-Medical Technology
Nanjing Chemlin Chemical
T&W GROUP
Shanghai Haoyuan Chemexpress
Shanghai Aladdin Bio-Chem Technology

Browse Full Research Report With TOC:
http://www.radiantinsights.com/research/china-rivastigmine-industry-2017

Market Segment by Regions (provinces), covering:

South China
East China
Southwest China
Northeast China
North China
Central China
Northwest China

Split by product Type, with production, revenue, price, market share and growth rate of each type, can be divided into:

Reagent Grade
Medical Grade

Split by Application, this report focuses on consumption, market share and growth rate of Rivastigmine in each application, can be divided into:

Chemical Reagents
Pharmaceutical Intermediates
Other

China Pyrazinamide Market Research And Analysis Report 2017 By Radiant Insights, Inc

This report studies Pyrazinamide in China market, focuses on the top players in China market, with capacity, production, price, revenue and market share for each manufacturer, covering:

Pure Chemistry Scientific
LGM Pharma
TCI
HBCChem
Alfa Chemistry
Toronto Research Chemicals
Acros Organics
AlliChem
Waterstone Technology
City Chemical
EDQM
J & K SCIENTIFIC
Meryer (Shanghai) Chemical Technology
Energy Chemical
Beijing Ouhe Technology

Browse Full Research Report With TOC: http://www.radiantinsights.com/research/china-pyrazinamide-industry-2017

Market Segment by Regions (provinces), covering:

South China
East China
Southwest China
Northeast China
North China
Central China
Northwest China

Split by product Type, with production, revenue, price, market share and growth rate of each type, can be divided into:

Purity 98%
Purity 99%
Other

Split by Application, this report focuses on consumption, market share and growth rate of Pyrazinamide in each application, can be divided into:

Children
Adult

See More Reports of This Category by Radiant Insights: http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare

Wednesday, 17 May 2017

Global Mobile Patient Lifts Industry Research And Trends Report 2016 By Radiant Insights, Inc

The Global Mobile Patient Lifts Market 2016 - Industry Research Report is a professional and in-depth study on the current state of the Mobile Patient Lifts industry.

Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Mobile Patient Lifts market analysis is provided for the international market including development history, competitive landscape analysis, and major regions' development status.

Browse Full Research Report With TOC: http://www.radiantinsights.com/research/global-mobile-patient-lifts-market-2016-industry-research-report

Secondly, development policies and plans are discussed as well as manufacturing processes and cost structures. This report also states import-export, supply and consumption figures as well as cost, price, revenue and gross margin by regions (North America, Europe, China and RoA), and other regions can be added.

Then, the report focuses on global major leading industry players with information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials, equipment and downstream consumer’s analysis is also carried out. What's more, the Mobile Patient Lifts industry development trends and marketing channels are analysed.

Finally, the feasibility of new investment projects is assessed, and overall research conclusions are offered.

In a word, the report provides major statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

See More Reports of This Category by Radiant Insights: http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare

Wednesday, 10 May 2017

Wiskott-Aldrich Syndrome Clinical Trials Review, H2, 2016 – Global Research Report By Radiant Insights, Inc

The clinical trial report Wiskott-Aldrich Syndrome Global Clinical Trials Review, H2, 2016 provides an overview of Wiskott-Aldrich Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Wiskott-Aldrich Syndrome. Report includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

Browse Full Research Report With TOC: http://www.radiantinsights.com/research/wiskott-aldrich-syndrome-global-clinical-trials-review-h2-2016

The report enhances the decision making capabilities and helps to create an effective counter strategy to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape

- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for accomplishment

- The Report provides enrolment trends for the past five years

- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons To Buy

- Assists in formulating key business strategies with regards to investment

- Helps in identifying prominent locations for conducting clinical trials which saves time and cost

- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

- Supports understanding of trials count and enrollment trends by country in global therapeutics market

- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

See More Reports of This Category by Radiant Insights: http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare

About Radiant Insights,Inc

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

Contact Details:

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

28 2nd Street, Suite 3036, San Francisco, CA 94105, United States

Phone: 1-415-349-0054

Toll Free: 1-888-202-9519

Email: sales@radiantinsights.com

Web: http://www.radiantinsights.com/

Von Willebrand Disease (Factor Viii Deficiency) Global Clinical Trials Review, H2, 2016: Growth Report: Radiant Insights, Inc

The clinical trial report Von Willebrand Disease (Factor VIII Deficiency) Global Clinical Trials Review, H2, 2016 provides an overview of Von Willebrand Disease (Factor VIII Deficiency) clinical trials scenario. This report provides top line data relating to the clinical trials on Von Willebrand Disease (Factor VIII Deficiency). Report includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

Browse Full Research Report With TOC: http://www.radiantinsights.com/research/von-willebrand-disease-factor-viii-deficiency-global-clinical-trials-review-h2-2016

The report enhances the decision making capabilities and helps to create an effective counter strategy to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape

- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

- The Report provides enrollment trends for the past five years